IPROC
Phase 2 Recruiting
60 enrolled
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Phase 2 Completed
275 enrolled 13 charts
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Phase 2 Completed
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
Phase 2 Completed
44 enrolled
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
Phase 2 Completed
122 enrolled
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
150 enrolled 11 charts
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2 Completed
30 enrolled 10 charts
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
50 enrolled
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Phase 2 Completed
22 enrolled
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Phase 2 Completed
81 enrolled
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
Phase 2 Completed
160 enrolled 10 charts
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase 2 Completed
60 enrolled 9 charts
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
28 enrolled 14 charts
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
31 enrolled 9 charts
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
81 enrolled 10 charts
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
24 enrolled 12 charts
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Terminated
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
51 enrolled 8 charts
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Terminated
23 enrolled 9 charts
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Phase 2 Completed
171 enrolled 10 charts
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
31 enrolled 12 charts
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
78 enrolled
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
27 enrolled
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
129 enrolled 17 charts
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase 2 Completed
35 enrolled 8 charts
S0009
Phase 2 Completed
62 enrolled 9 charts
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
Phase 2 Unknown
118 enrolled
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Phase 2 Completed
76 enrolled
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
Phase 2 Completed
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Withdrawn
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Terminated
Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
Phase 2 Terminated
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
Phase 2 Withdrawn
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
Phase 2 Completed
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Phase 2 Terminated
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
Phase 2 Terminated
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
Phase 2 Terminated
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase 2 Terminated
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Terminated
S9912 Combination Chemo in Stage III Ovarian Cancer,
Phase 2 Completed
68 enrolled 8 charts
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
132 enrolled
Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer
Phase 2 Completed
51 enrolled